Ischemia-Modifi ed Albumin Levels in Children with Chronic Liver Disease
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Ischemia-modifi ed albumin (IMA) levels have been shown to correlate with the severity of liver failure in adults. However, the role of IMA levels has not been evaluated in children with chronic liver disease (CLD). We analyzed the clinical significance of IMA levels in children with CLD. Methods: Thirty-three children with CLD and 33 healthy children were included in the study. Blood was collected to analyze biochemical parameters, oxidant status, and IMA. Liver biopsies were re-evaluated for liver fibrosis; severe fibrosis (SF) was defi ned as fi brosis stage ≥4. Results: The IMA and and IMA to albumin ratios (IMARs) were signifi cantly higher in children with CLD than in those without (IMA: 0.545±0.095vs 0.481±0.062, p=0.003; IMAR: 0.152±0.046 vs 0.126±0.018, p=0.04). The IMAR was positively correlated with the pediatric end-stage liver disease score (p=0.03,r=0.503) and fibrosis score (p=0.021, r=0.400). Patients with SF had higher IMARs compared to patients with mild fi brosis (0.181±0.056 vs 0.134±0.025, p=0.003). The area under the receiver operation curve (AUROC) for predicting SF was 0.78 (p=0.006). Using a cutoff ratio value of 0.140, the sensitivity and specificity were 84% and 70%, respectively. The AUROC for predicting the need for liver transplantation and/or death was 0.82 (p=0.013). With a cutoff value of 0.156, the sensitivity and specifi city was 83% and 82%, respectively. Kaplan-Meier analysis revealed increased morbidity and/or mortality in the group with an IMAR>0.156 (50%vs 4.3%, p=0.005). Conclusions: IMARs have been shown to provide important clues in predicting the fi brosis stage of the disease and determining the outcome in children with CLD.
Abstract
Background/Aims: Ischemia-modifi ed albumin (IMA) levels have been shown to correlate with the severity of liver failure in adults. However, the role of IMA levels has not been evaluated in children with chronic liver disease (CLD). We analyzed the clinical significance of IMA levels in children with CLD. Methods: Thirty-three children with CLD and 33 healthy children were included in the study. Blood was collected to analyze biochemical parameters, oxidant status, and IMA. Liver biopsies were re-evaluated for liver fibrosis; severe fibrosis (SF) was defi ned as fi brosis stage ≥4. Results: The IMA and and IMA to albumin ratios (IMARs) were signifi cantly higher in children with CLD than in those without (IMA: 0.545±0.095vs 0.481±0.062, p=0.003; IMAR: 0.152±0.046 vs 0.126±0.018, p=0.04). The IMAR was positively correlated with the pediatric end-stage liver disease score (p=0.03,r=0.503) and fibrosis score (p=0.021, r=0.400). Patients with SF had higher IMARs compared to patients with mild fi brosis (0.181±0.056 vs 0.134±0.025, p=0.003). The area under the receiver operation curve (AUROC) for predicting SF was 0.78 (p=0.006). Using a cutoff ratio value of 0.140, the sensitivity and specificity were 84% and 70%, respectively. The AUROC for predicting the need for liver transplantation and/or death was 0.82 (p=0.013). With a cutoff value of 0.156, the sensitivity and specifi city was 83% and 82%, respectively. Kaplan-Meier analysis revealed increased morbidity and/or mortality in the group with an IMAR>0.156 (50%vs 4.3%, p=0.005). Conclusions: IMARs have been shown to provide important clues in predicting the fi brosis stage of the disease and determining the outcome in children with CLD.
참고문헌 (20)
- Quinlan GJ, "Albumin: biochemical properties and therapeutic potential", Hepatology, 41, pp.1211~1219 (2005)
- Arroyo V, "Human serum albumin: not just a plasma volume expander", Hepatology, 50, pp.355~357 (2009)
- Sort P, "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis", N Engl J Med, 341, pp.403~409 (1999)
- Collinson PO, "Ischaemia-modified albumin: clinical utility and pitfalls in measurement", J Clin Pathol, 61, pp.1025~1028 (2008)
- Bar-Or D, "A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report", J Emerg Med, 19, pp.311~315 (2000)
- Roy D, "Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin", Heart, 92, pp.113~114 (2006)
- Sbarouni E, "Ischemia modified albumin changes: review and clinical implications", Clin Chem Lab Med, 49, pp.177~184 (2011)
- Turedi S, "Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population", J Nephrol, 23, pp.335~340 (2010)
- Dahiya K, "Type 2 diabetes mellitus without vascular complications and ischemia modified albumin", Clin Lab, 56, pp.187~190 (2010)
- Jalan R, "Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality", Hepatology, 50, pp.555~564 (2009)
- Pugh RN, "Transection of the oesophagus for bleeding oesophageal varices", Br J Surg, 60, pp.646~649 (1973)
- McDiarmid SV, "Selection of pediatric candidates under the PELD system", Liver Transpl, 10(10 Suppl 2), pp.S23~S30 (2004)
- Erel O, "A new automated colorimetric method for measuring total oxidant status", Clin Biochem, 38, pp.1103~1111 (2005)
- Erel O, "A novel automated method to measure total antioxidant response against potent free radical reactions", Clin Biochem, 37, pp.112~119 (2004)
- Standish RA, "An appraisal of the histopathological assessment of liver fibrosis", Gut, 55, pp.569~578 (2006)
- Schwimmer JB, "Prevalence of fatty liver in children and adolescents", Pediatrics, 118, pp.1388~1393 (2006)
- Klammt S, "Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for endstage liver disease", Eur J Gastroenterol Hepatol, 19, pp.257~263 (2007)
- Gunduz A, "Serum ischaemia-modified albumin increases in critical lower limb ischaemia", Emerg Med J, 25, pp.351~353 (2008)
- Carey E, "Noninvasive tests for liver disease, fibrosis, and cirrhosis: is liver biopsy obsolete?", Cleve Clin J Med, 77, pp.519~527 (2010)
- Wiesner RH, "MELD and PELD: application of survival models to liver allocation", Liver Transpl, 7, pp.567~580 (2001)